You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
This is the first update to the guidelines since 2010, and the agency specifically calls out two of the three FDA-cleared Trichomonas NAATs.
The number of decliners in the GenomeWeb Index in April outpaced the gainers 24 to seven amid softness in the broader biotech market.
The presentations were part of a Quidel-sponsored workshop and poster sessions at the Clinical Virology Symposium in Daytona Beach, Fla.
New product revenues more than doubled year over year, while infectious disease test revenues grew 35 percent.
The trichomonas assay is Quidel's sixth assay running on the AmpliVue handheld molecular diagnostic device that has been cleared by the FDA.
Roche's investment in Foundation of up to $1.2B sent Foundation's stock soaring. Otherwise, firms in the GenomeWeb Index saw a mixed month.
The company expects revenues in the range of $63 million to $64 million for the fourth quarter and $182 million to $183 million for full-year 2014.
Trends included expanding test menus and a possible tipping point for point-of-care.
The clearance is the fourth for a Quidel test on the AmpliVue handheld MDx format.
The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.
The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.
Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.
In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.